Search Results:
CLINICAL TRIAL 19868
First in Human Phase I Study of 225Actinium-DOTA-Ahx-MC1RL (225Ac-MTI-201) in Metastatic Melanoma
Disease Site: Eye and Orbit, Melanoma, skin
View Trial DetailsCLINICAL TRIAL 20162
Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma
Disease Site: Melanoma, skin, Merkel cell carcinoma, Other Skin, Skin, Squamous Cell Carcinoma (SCC)
View Trial DetailsCLINICAL TRIAL 20270
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors (IOV-COM-202)
Disease Site: Lung, Melanoma, skin, Non small cell lung cancer
View Trial DetailsCLINICAL TRIAL 20313
Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 20641
A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 20854
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Disease Site: Melanoma, skin, Other Skin
View Trial DetailsCLINICAL TRIAL 20904
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in Braf-V600 Mutant Melanoma with Brain Metastases
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21080
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (DRAGON)
Disease Site: Any Site, Lung, Melanoma, skin, Urinary Bladder
View Trial DetailsCLINICAL TRIAL 21112
Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21180
A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)
Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder
View Trial DetailsCLINICAL TRIAL 21239
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21273
A Randomized, Pilot Study to Evaluate the Molecular and Cellular Response to Treatment with Nivolumab with either Adjuvant Ipilimumab or Relatlimab in Adult Patients with Surgically Resectable Melanoma Brain Metastases
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21344
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma)
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21553
A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21573
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients with Hepatic Dominant Ocular Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21707
A Proof of Concept Study of TBio-4101 (an autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) using Short-Term Cultured, Selected Autologous TIL Following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Melanoma (Phase 1)
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21731
A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 22284
A Phase lb Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)
Disease Site: Breast, Colon, Melanoma, skin, Rectum
View Trial DetailsCLINICAL TRIAL 21125
MElanoma Research Lymph Node Prediction Implementation National_001 (MERLIN_001)
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21942
Characterization of Lymphoid Aggregates in Desmoplastic Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 22505
Cutaneous Adverse Events (irCAEs) Associated with Immunotherapy in Patients with Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 22536
Immune Profiling of Relatlimab and Nivolumab Combination Immunotherapy for Advanced Stage Metastatic Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 50401
Creation of Cell Lines and Corresponding DNA and RNA Analysis from Acral Lentiginous Malignant Melanoma
Disease Site: Melanoma, skin
View Trial Details
